9 Article(s)Download |
PMID | Title | Pub. Year | #Total Relationships |
1 | 35110965 | Treatment Response to Immunotherapy After Crizotinib Resistance in a Patient With Pulmonary Sarcomatoid Carcinoma Harboring MET Exon 14 Skipping Mutation: A Case Report. | 2022 | 1 |
2 | 35405360 | Investigation on the survival implications of PD-L1 expression status in ALK- rearranged advanced non-small cell lung cancer treated with first-line crizotinib. | 2022 May | 5 |
3 | 34428672 | Multiplexed electrokinetic sensor for detection and therapy monitoring of extracellular vesicles from liquid biopsies of non-small-cell lung cancer patients. | 2021 Dec 1 | 1 |
4 | 32386255 | Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib. | 2020 Aug | 6 |
5 | 31098955 | PD-L1 Expression and Its Regulation in Lung Adenocarcinoma with ALK Translocation. | 2019 Jun | 2 |
6 | 28978110 | Increased PD-L1 expression in erlotinib-resistant NSCLC cells with MET gene amplification is reversed upon MET-TKI treatment. | 2017 Sep 15 | 1 |
7 | 27141355 | Upregulation of PD-L1 by EML4-ALK fusion protein mediates the immune escape in ALK positive NSCLC: Implication for optional anti-PD-1/PD-L1 immune therapy for ALK-TKIs sensitive and resistant NSCLC patients. | 2016 Mar | 2 |
8 | 27141364 | EML4-ALK enhances programmed cell death-ligand 1 expression in pulmonary adenocarcinoma via hypoxia-inducible factor (HIF)-1α and STAT3. | 2016 Mar | 3 |
9 | 27753543 | STAT3-targeted treatment with silibinin overcomes the acquired resistance to crizotinib in ALK-rearranged lung cancer. | 2016 Dec 16 | 1 |